Resources Archive - Page 5 of 45

Synthetic Lethality Related Tumor Models

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like...

Polycythemia Vera Disease Mouse Models

Polycythemia vera (PV) is a chronic myeloproliferative disorder, a type of blood cancer characterized by the overproduction of red blood...

Platform Supporting the Discovery of Agents against HSV

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of...

Epilepsy Animal Models

Epilepsy is a chronic brain disorder characterized by recurring seizures, which are episodes of uncontrolled and abnormal electrical activity in...

Rare Neurological Disease Animal Models

Rare neurological diseases are conditions affecting the nervous system that occur infrequently, with examples including Huntington’s disease, Rett syndrome, and...

Rational Design and Optimization of a Potent IDO1 PROTAC

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors...

Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies...

Asthma Services Platform

Asthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with...

Therapeutic Potential of Polatuzumab Vedotin for the Treatment of DLBCL

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a...

Knowledge Library